Cervarix 1 dose (0,5 mL) Suspensions for injection.
PDF Leaflet Revision Date: 24 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of HPV-related cancers and lesions in individuals from 9 years of age.
Dosage (summary)
9-14 years: 2 doses (0.5 mL) at 0 and 5-13 months; 15 years and older: 3 doses (0.5 mL) at 0, 1, 6 months.
Special Populations
- Immunocompromised individuals
- Children < 9 years
Pregnancy & Breastfeeding
Postpone vaccination during pregnancy; use during breastfeeding only if benefits outweigh risks.
Key Drug Interactions
- Concomitant use with other vaccines
- Hormonal contraceptives
Contraindications
- Hypersensitivity to vaccine components
Common side effects
- Injection site pain
- Headache
- Fatigue
- Myalgia
- Fever
Counselling Points
- Inform about potential side effects
- Encourage regular cervical screening
- Discuss vaccination schedule
Serious warnings
- Risk of syncope
- Not for treatment of existing HPV lesions
- No protection against all HPV types
Important Disclaimer
The Cervarix 1 dose (0,5 mL) Suspensions for injection. professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
